Optimizing the "Drug-Like" Properties of Leads in Drug Discovery [electronic resource] / edited by Ronald Borchardt, Edward Kerns, Michael Hageman, Dhrien Thakker, James Stevens.

9780387449616

1st ed. 2006.

New York, NY : Springer New York : Imprint: Springer, 2006.

1 online resource (X, 512 p.) 190 illus., 39 illus. in color.

Access is available to the Yale community.

Access restricted by licensing agreement.

Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, “drug-like” properties refer to the molecule’s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.

Springer ENIN.

Books / Online

English

September 20, 2019